Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging

Ahmed Tawakol; Parmanand Singh; James H.F. Rudd; Joseph Soffer; Gengqian Cai; Esad Vucic; Sarah P. Brannan; Elizabeth A. Tarka; Bonnie C. Shaddinger; Lea Sarov-Blat; Paul Matthews; Sharath Subramanian; Michael Farkouh; Zahi A. Fayad

doi:10.1016/j.jacc.2013.07.050

Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A₂ inhibitor, on arterial inflammation as assessed with ¹⁸F-fluorodeoxyglucose-positron emission tomography imaging

Ahmed Tawakol, Parmanand Singh, James H.F. Rudd, Joseph Soffer, Gengqian Cai, Esad Vucic, Sarah P. Brannan, Elizabeth A. Tarka, Bonnie C. Shaddinger, Lea Sarov-Blat, Paul Matthews, Sharath Subramanian, Michael Farkouh, Zahi A. Fayad

Research output: Contribution to journal › Letter › peer-review

77 Scopus citations

Original language	English
Pages (from-to)	86-88
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	63
Issue number	1
DOIs	https://doi.org/10.1016/j.jacc.2013.07.050
State	Published - 1 Jan 2014

Access to Document

10.1016/j.jacc.2013.07.050

Cite this

Tawakol, A., Singh, P., Rudd, J. H. F., Soffer, J., Cai, G., Vucic, E., Brannan, S. P., Tarka, E. A., Shaddinger, B. C., Sarov-Blat, L., Matthews, P., Subramanian, S., Farkouh, M., & Fayad, Z. A. (2014). Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A₂ inhibitor, on arterial inflammation as assessed with ¹⁸F-fluorodeoxyglucose-positron emission tomography imaging. Journal of the American College of Cardiology, 63(1), 86-88. https://doi.org/10.1016/j.jacc.2013.07.050

@article{35cf8604d64748118044d36a86614e92,

title = "Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging",

author = "Ahmed Tawakol and Parmanand Singh and Rudd, {James H.F.} and Joseph Soffer and Gengqian Cai and Esad Vucic and Brannan, {Sarah P.} and Tarka, {Elizabeth A.} and Shaddinger, {Bonnie C.} and Lea Sarov-Blat and Paul Matthews and Sharath Subramanian and Michael Farkouh and Fayad, {Zahi A.}",

note = "Funding Information: Please note: Funding for this study and for editorial assistance with the preparation of the manuscript were provided by GlaxoSmithKline, PLC . Dr. Tawakol has reported that he has received grants from the National Institutes of Health , Genetech , and Bristol-Myers Squibb ; and consulting fees from Genetech/Roche, Bristol-Myers Squibb, Novartis, Cerenis, and Siemens. Dr. Rudd has reported that his work has been supported by the National Institute for Health Research Cambridge Biomedical Research Centre , the British Heart Foundation , the Academy of Medical Sciences , and the Higher Education Funding Council for England ; and he has received support from Roche and Genetech . Drs. Soffer, Cai, Brannan, Tarka, Shaddinger, Sarov-Blat, and Matthews are employees, with stock and stock options, of GlaxoSmithKline. Dr. Matthews has received honoraria from Novartis. Dr. Fayad has received research grants from Roche , GlaxoSmithKline , Merck , VBL Therapeutics , Novartis, Bristol-Myers Squibb ; and honoraria from Roche. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Tawakol and Singh contributed equally to this work. (The Stabilization of Plaques Using Darapladib Thrombolysis In Myocardial Infarction 52 Trial [SOLID-TIMI 52]; NCT01000727 ; The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903 ; An Imaging Study in Patients With Atherosclerosis Taking Rilapladib of Placebo for 12 Weeks; NCT00695305 ). ",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.jacc.2013.07.050",

language = "English",

volume = "63",

pages = "86--88",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "1",

}

Tawakol, A, Singh, P, Rudd, JHF, Soffer, J, Cai, G, Vucic, E, Brannan, SP, Tarka, EA, Shaddinger, BC, Sarov-Blat, L, Matthews, P, Subramanian, S, Farkouh, M & Fayad, ZA 2014, 'Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A₂ inhibitor, on arterial inflammation as assessed with ¹⁸F-fluorodeoxyglucose-positron emission tomography imaging', Journal of the American College of Cardiology, vol. 63, no. 1, pp. 86-88. https://doi.org/10.1016/j.jacc.2013.07.050

Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A₂ inhibitor, on arterial inflammation as assessed with ¹⁸F-fluorodeoxyglucose-positron emission tomography imaging. / Tawakol, Ahmed; Singh, Parmanand; Rudd, James H.F. et al.
In: Journal of the American College of Cardiology, Vol. 63, No. 1, 01.01.2014, p. 86-88.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging

AU - Tawakol, Ahmed

AU - Singh, Parmanand

AU - Rudd, James H.F.

AU - Soffer, Joseph

AU - Cai, Gengqian

AU - Vucic, Esad

AU - Brannan, Sarah P.

AU - Tarka, Elizabeth A.

AU - Shaddinger, Bonnie C.

AU - Sarov-Blat, Lea

AU - Matthews, Paul

AU - Subramanian, Sharath

AU - Farkouh, Michael

AU - Fayad, Zahi A.

N1 - Funding Information: Please note: Funding for this study and for editorial assistance with the preparation of the manuscript were provided by GlaxoSmithKline, PLC . Dr. Tawakol has reported that he has received grants from the National Institutes of Health , Genetech , and Bristol-Myers Squibb ; and consulting fees from Genetech/Roche, Bristol-Myers Squibb, Novartis, Cerenis, and Siemens. Dr. Rudd has reported that his work has been supported by the National Institute for Health Research Cambridge Biomedical Research Centre , the British Heart Foundation , the Academy of Medical Sciences , and the Higher Education Funding Council for England ; and he has received support from Roche and Genetech . Drs. Soffer, Cai, Brannan, Tarka, Shaddinger, Sarov-Blat, and Matthews are employees, with stock and stock options, of GlaxoSmithKline. Dr. Matthews has received honoraria from Novartis. Dr. Fayad has received research grants from Roche , GlaxoSmithKline , Merck , VBL Therapeutics , Novartis, Bristol-Myers Squibb ; and honoraria from Roche. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Tawakol and Singh contributed equally to this work. (The Stabilization of Plaques Using Darapladib Thrombolysis In Myocardial Infarction 52 Trial [SOLID-TIMI 52]; NCT01000727 ; The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903 ; An Imaging Study in Patients With Atherosclerosis Taking Rilapladib of Placebo for 12 Weeks; NCT00695305 ).

PY - 2014/1/1

Y1 - 2014/1/1

UR - http://www.scopus.com/inward/record.url?scp=84891812420&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.07.050

DO - 10.1016/j.jacc.2013.07.050

M3 - Letter

C2 - 23973698

AN - SCOPUS:84891812420

SN - 0735-1097

VL - 63

SP - 86

EP - 88

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 1

ER -

Tawakol A, Singh P, Rudd JHF, Soffer J, Cai G, Vucic E et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A₂ inhibitor, on arterial inflammation as assessed with ¹⁸F-fluorodeoxyglucose-positron emission tomography imaging. Journal of the American College of Cardiology. 2014 Jan 1;63(1):86-88. doi: 10.1016/j.jacc.2013.07.050